315 related articles for article (PubMed ID: 32434734)
1. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
2. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of RNA-binding proteins in human cancers.
Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
5. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Lu SX; De Neef E; Thomas JD; Sabio E; Rousseau B; Gigoux M; Knorr DA; Greenbaum B; Elhanati Y; Hogg SJ; Chow A; Ghosh A; Xie A; Zamarin D; Cui D; Erickson C; Singer M; Cho H; Wang E; Lu B; Durham BH; Shah H; Chowell D; Gabel AM; Shen Y; Liu J; Jin J; Rhodes MC; Taylor RE; Molina H; Wolchok JD; Merghoub T; Diaz LA; Abdel-Wahab O; Bradley RK
Cell; 2021 Jul; 184(15):4032-4047.e31. PubMed ID: 34171309
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
10. Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.
Gibbs ZA; Whitehurst AW
Trends Cancer; 2018 Oct; 4(10):701-712. PubMed ID: 30292353
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia alters splicing of the cancer associated Fas gene.
Peciuliene I; Vilys L; Jakubauskiene E; Zaliauskiene L; Kanopka A
Exp Cell Res; 2019 Jul; 380(1):29-35. PubMed ID: 31002816
[TBL] [Abstract][Full Text] [Related]
13. Targeting splicing abnormalities in cancer.
Agrawal AA; Yu L; Smith PG; Buonamici S
Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
[TBL] [Abstract][Full Text] [Related]
14. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
[TBL] [Abstract][Full Text] [Related]
15. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
[TBL] [Abstract][Full Text] [Related]
16. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
17. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
18. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
Liang Z; Kidwell RL; Deng H; Xie Q
Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
[TBL] [Abstract][Full Text] [Related]
20. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]